Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". - Gerischer, Lea; Schroeder‐Braunstein, Jutta; Wabnitz, Guido; Meisel, Andreas (Annals of Clinical & Translational Neurology, 2026)